ELSEVIER

Contents lists available at ScienceDirect

Journal of Mass Spectrometry and Advances in the Clinical Lab

journal homepage: www.sciencedirect.com/journal/journal-of-massspectrometry-and-advances-in-the-clinical-lab





Corrigendum to "Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer's disease" [Clin. Mass Spectrom. 14 (Part B) (2019) 74–82]

Karl Hansson ^a, Rahil Dahlén ^a, Oskar Hansson ^{b,c}, Elin Pernevik ^a, Ross Paterson ^d, Jonathan M. Schott ^d, Nadia Magdalinou ^e, Henrik Zetterberg ^{a,f}, Kaj Blennow ^{a,f}, Johan Gobom ^{a,f,*}

- ^a Institute of Neuroscience and Physiology, Department of Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden
- ^b Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden
- ^c Memory Clinic, Skåne University Hospital, Malmö, Sweden
- d Dementia Research Centre, UCL Institute of Neurology, London, UK
- e Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, Queen Square, London, UK
- f Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden

Following a request for better clarity around ethics and informed consent in obtaining the patient samples, the authors would like to add the following information to the above mentioned paper: "Informed consent and Institutional Review Board (IRB)/Ethics Committee approval were obtained."

E-mail address: johan.gobom@neuro.gu.se (J. Gobom).

DOI of original article: https://doi.org/10.1016/j.clinms.2019.07.002.

^{*} Corresponding author at: Institute of Neuroscience and Physiology, Department of Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, 431 80 Mölndal, Sweden.